2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2663

Antimalarials Protect Against Damage Accrual in Primary SjöGren’s Syndrome
Abstract Number: 2845

Antineutrophil Cytoplasmic Antibodies in Systemic Lupus Erythematosus: Incidence, Outcome and Prognosis
Abstract Number: 1946

Antineutrophil Cytoplasmic Antibody (ANCA) Type and Body Mass Index in ANCA-Associated Vasculitis (AAV)
Abstract Number: 1060

Antiphospholipid Antibodies and Related Clinical Events Following Infection in Children: A Systematic Review of Case Reports
Abstract Number: 1073

Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking (APS ACTION) Clinical Database and Repository Analysis: The Comparison of Real World and Core Laboratory Antiphospholipid Antibody ELISA Results
Abstract Number: 1072

Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: Cardiovascular Risk Factors Among Different Groups of Antiphospholipid Antibody-Positive Patients
Abstract Number: 1064

Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: Direct Oral Anticoagulant Use Among Antiphospholipid Syndrome Patients
Abstract Number: 1965

Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking Registry Analysis: First and Recurrent Thrombosis Risk after 720 Patient-Years of Follow-up
Abstract Number: 1962

Antiphospholipid Syndrome Neutrophils Are Characterized By Overexpression of P-Selectin Glycoprotein Ligand 1, a Potential Therapeutic Target
Abstract Number: 2091

Antiphospholipid Syndrome Patients’ Time within Therapeutic Range of International Normalized Ratio (INR)
Abstract Number: 2961

Antiphospoholipid Antibodies in Adult IgA Vasculitis: Aps/PT Antibodies As a Potential Marker of Renal Involvement?
Abstract Number: 3184

Antiphospoholipid Antibodies in Giant Cell Arteritis. What Can They Tell Us?
Abstract Number: 1527

Anxiety Sensitivity on Indicators of Disease Severity Among Patients with Inflammatory Arthritis
Abstract Number: 374

Anxiolytic Effects of the Novel α2δ Ligand Mirogabalin (DS-5565) in Sluka Model, an Experimental Animal Model of Fibromyalgia
Abstract Number: 2263

Apolipoprotein E Regulates Inflammation and Joint Destruction during Antigen-Induced Arthritis (AIA)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].